Korro Bio (KRRO) director Ali Behbahani receives 14,677 stock options grant

Rhea-AI Filing Summary

Korro Bio director Ali Behbahani received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options were awarded at no upfront cost and expire on June 9, 2036.

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director. Following this award, Behbahani holds 14,677 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Behbahani Ali

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,677	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,677 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 14,677 options Exercise price: $10.59 per share Expiration date: June 9, 2036 +1 more

4 metrics

Options granted 14,677 options Stock option award to director Ali Behbahani

Exercise price $10.59 per share Stock option strike price

Expiration date June 9, 2036 Option term end date

Post-transaction options held 14,677 options Total derivative holdings after grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "10.5900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.59	06/10/2026		A		14,677		(1)	06/09/2036	Common Stock	14,677	$0	14,677	D

Explanation of Responses:

1. The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.

	/s/ Zachary Bambach, attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Korro Bio (KRRO) director Ali Behbahani report in this Form 4?

Ali Behbahani reported receiving a grant of stock options for 14,677 shares of Korro Bio common stock. The options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price of $10.59.

How many Korro Bio (KRRO) stock options did Ali Behbahani receive?

He received stock options covering 14,677 shares of Korro Bio common stock. This entire amount was granted in a single award, and his total derivative holdings after the transaction are 14,677 stock options held directly.

What is the exercise price and expiration date of Ali Behbahani’s Korro Bio options?

The options have an exercise price of $10.59 per share and expire on June 9, 2036. This means he can choose to purchase shares at $10.59 any time before the June 2036 expiration, once the options have vested.

When do Ali Behbahani’s Korro Bio (KRRO) stock options vest?

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders. Vesting is conditioned on his continued service as a non-employee director through the applicable vesting date.

Did Ali Behbahani buy or sell Korro Bio (KRRO) shares in the market?

No open-market buy or sell occurred; this was a grant of stock options as compensation. The Form 4 shows an acquisition coded as a grant or award, with no reported sales or purchases of common stock in the market.

How significant is this Korro Bio (KRRO) Form 4 transaction?

The filing reflects a routine director compensation award of 14,677 stock options. It does not show any discretionary buying or selling activity, so it mainly updates investors on Ali Behbahani’s equity-based incentives and potential future share ownership.